- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
BIO-Europe 2007
BIO-Europe 2007
BIO-Europe 2007 Global Biotech Partnering Conference Congress Center, Hamburg, Germany, November 12-14, 2007
The 13th annual BIO-Europe event is the world's largest stand-alone biotechnology partnering conference. Almost two thousand global decision-makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry's most advanced web-based partnering system, enabling delegates from all parts of the biotechnology value-chain to quickly identify, engage and enter into the strategic relationships that drive their business successfully forward.
BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in partnership with the Biotechnology Industry Organization (BIO) and European Biopharmaceutical Enterprises (EBE).
For more information and online registration please visit our conference website at www.ebdgroup.com/bioeurope
Or contact:
Tom Voigt
EBD Group
Phone: +1 (760) 930 0500
Fax: +1 (760) 930 0520
tvoigt@ebdgroup.com
Companies located in Europe may also contact:
Annika Rudat
EBD Group
Phone: +49 (89) 23 88 756 - 0
Fax: +49 (89) 23 88 756 - 55
arudat@ebdgroup.com
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
